[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-edema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-edema":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,67,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100645254","tens-of-auricular-vagal-nerve-for-radiation-necrosis-100645254",false,"NCT07680127","TENS of Auricular Vagal Nerve for Radiation Necrosis","Transcutaneous Auricular Vagal Nerve Stimulation for Treatment of Radiation Necrosis","Inclusion Criteria:\n\n* History of glioma or metastatic brain lesion previously treated with whole brain radiation, stereotactic radiation surgery, or fractionated radiation therapy\n* Magnetic resonance imaging (MRI) findings consistent with possible radiation necrosis within 6 weeks prior to enrollment.\n* Candidate for tissue biopsy and Laser Interstitial Thermal Therapy (LITT) ablation of the lesion\n* At least 18 years of age\n* If on corticosteroids, able to discontinue at least 5 days prior to start of transcutaneous auricular vagus nerve stimulation (taVNS) (Arm 1) or sham treatment (Arm 2). A stable physiologic dose of corticosteroids, if used as hormone replacement therapy, may be allowed upon discussion with the investigator. 6. Ability to understand and willingness to sign an institutional review board (IRB) approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* New onset neurologic deficits secondary to radiation necrosis requiring initiation of dexamethasone therapy or other intervention prior to enrollment\n* Currently receiving bevacizumab for treatment of radiation necrosis or has received bevacizumab \\\u003C 6 weeks prior to study enrollment.\n* Currently receiving any investigational agents for treatment of radiation necrosis or has participated in a study of an investigational agent for radiation necrosis within 3 weeks prior to study enrollment.\n* History of cardiac conduction disorders or presence of implanted electronic devices\n* Active Crohn's disease or other inflammatory bowel disease.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a multi-center, randomized, blinded trial evaluating the effect of transcutaneous auricular vagal nerve stimulator (taVNS) on radiation necrosis-related cerebral edema. In this study, consenting and eligible patients will be assigned to one of two arms: treatment (Arm 1) or sham (Arm 2). Patients in both arms will have imaging performed and tissue and blood collected for assessment of changes in area of contrast enhancement and cerebral edema, inflammatory markers, and markers of blood-brain barrier permeability.",[26,27],"Radiation Necrosis","Cerebral Edema",[26],"NOT_YET_RECRUITING","2026-06-25",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":20},"2026-07-31",{"date":37,"type":20},"2029-08-31",{"name":39,"class":40},"Virginia Commonwealth University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100622641","a-trial-of-adacolumn-on-cerebral-edema-after-anterior-circulation-ischemic-stroke-100622641","NCT07386262","A Trial of Adacolumn on Cerebral Edema After Anterior Circulation Ischemic Stroke","Efficacy and Safety of the Adacolumn® Granulocyte and Monocyte\u002FMacrophage Apheresis Device for Cerebral Edema After Acute Anterior Circulation Occlusive Cerebral Infarction: A Prospective, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. A clinical diagnosis of acute ischemic stroke;\n3. Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA or DSA;\n4. NIHSS score ≥10 at screening;\n5. Pre-stroke mRS score \\\u003C2 (independent in all activities of daily living);\n6. Time from stroke onset to initiation of the first Adacolumn treatment is ≤24 hours, stroke onset is defined as the last time the patient was known to be at their neurological baseline (wake-up strokes qualify if within this time window);\n7. All endovascular thrombectomy procedures must strictly adhere to the \"2024 Chinese Stroke Association Guidelines for Reperfusion Therapy in Acute Ischemic Stroke\" and the latest prescribing information\u002Finstructions for use regarding indications, contraindications, and procedural standards;\n8. Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Decompressive craniectomy performed before enrollment or between enrollment and initiation of study treatment;\n2. Patients who receive intravenous thrombolysis (including bridging therapy) for the index ischemic stroke episode before or during endovascular thrombectomy; or undergo permanent intracranial or extracranial stent implantation (including intracranial stent-assisted thrombectomy or carotid stenting) during the index endovascular procedure;\n3. After endovascular thrombectomy: extensive contrast extravasation (diffuse subarachnoid high density or parenchymal high density not consistent with hematoma), new subarachnoid hemorrhage（SAH）, or symptomatic intracranial hemorrhage (sICH);\n4. Large-vessel occlusion is attributed to other determined etiologies per TOAST classification, such as tumor-related, dissection-related, or other clearly identifiable non-LAA\u002Fnon-CE causes.\n5. Clinical signs of brain herniation, such as unilateral or bilateral fixed dilated pupils and\u002For other loss of brainstem reflexes attributable to cerebral edema or herniation in the investigator's opinion;\n6. Intracranial lesions conferring markedly increased bleeding risk (known brain tumor, arteriovenous malformation, aneurysm);\n7. Inability to undergo MRI;\n8. Absolute neutrophil count \\\u003C1.5×10⁹\u002FL or \\>15×10⁹\u002FL\n9. Absolute monocyte count \\> 1.0 ×10⁹\u002FL;\n10. Red blood cells \\\u003C3.0×10¹²\u002FL ;\n11. Active internal bleeding or bleeding tendency (such as platelet count \\\u003C100×10⁹\u002FL, INR \\>1.7, PT \\>15 seconds);\n12. Marked hypercoagulability (fibrinogen \\>700 mg\u002FdL);\n13. Intracranial or spinal surgery or severe head trauma within the past 3 months;\n14. Refractory hypertension (persistent systolic blood pressure \\>185 mmHg or diastolic \\>110 mmHg);\n15. Known allergy to components of the blood purification system (including adsorption membrane, anticoagulants);\n16. Acute ST-segment elevation myocardial infarction and\u002For acute decompensated heart failure and\u002For corrected QT interval \\>520 ms and\u002For history of cardiac arrest within the past 6 months(pulseless electrical activity, ventricular tachycardia, ventricular fibrillation, or asystole);\n17. Body temperature \\>38°C or active infection;\n18. Active autoimmune disease or immunodeficiency;\n19. Participation in another interventional clinical trial within the past 30 days;\n20. Any other condition deemed unsuitable for participation by the investigator.","80 Years",{"count":51,"type":20},10,[23],"The primary objective is to investigate whether treatment with Adacolumn can ameliorate the progression of cerebral edema within 72 hours in patients with anterior circulation ischemic stroke. The secondary objective is to explore if Adacolumn could improve acute neurologic status, functional outcomes, treatment requirements and safety in patients with anterior circulation ischemic stroke.",[27,55,56,57],"Ischemic Stroke, Acute","Malignant Cerebral Edema","Anterior Circulation Brain Infarction","2026-05-03",{"date":60,"type":33},"2026-05-05",{"date":62,"type":20},"2026-05-01",{"date":64,"type":20},"2028-12-31",{"name":66,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100602041","early-prophylactic-decompressive-hemicraniectomy-following-endovascular-therapy-in-large-hemispheric-infarct-trial-100602041","NCT07118345","Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial","1. Premorbid mRS ≤1;\n2. Time from symptom onset to puncture ≤24 hours; including wake-up stroke and unwitnessed stroke. The time at which symptoms began was defined as the \"Last Known Well\" (LKW).\n\n3.18 to 75 years of age; 4.Internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 occlusion confirmed by computed tomographic angiography (CTA)\u002F magnetic resonance angiography (MRA)\u002F digital subtraction angiography (DSA). Patients with involvement of ipsilateral anterior cerebral artery (ACA), MCA or embryonal posterior cerebral artery (PCA) are eligible for inclusion.\n\n5.NIHSS1a ≥ 1 (with the clarification that changes in alertness cannot be attributable to cerebral edema); 6.Meeting any of the following criteria:\n\n1. ASPECTS 3-5 and NIHSS ≥ 30;\n2. ASPECTS 0-2; 7.Signs on CT\u002FMRI of an infarct of at least 50% of the middle cerebral artery territory; 8.No midline shift or midline shift \\\u003C5mm; 9.Mechanical Thrombectomy and successful recanalization (defined as eTICI ≥2b50); 10.Ability to initiate decompressive hemicraniectomy within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization; 11.Informed consent obtained from the patient or his\u002Fher legal representative.\n\nExclusion Criteria:\n\nClinical Exclusion Criteria\n\n1. Any symptoms and signs of brain herniation before randomization, such as pupil anisocoria and unstable vital signs.\n2. In the judgment of the investigator, the subject is likely to have supportive care withdrawn in the first day.\n3. Commitment to decompressive hemicraniectomy (DHC) prior to enrollment.\n4. Severe, sustained hypertension (systolic blood pressure \\> 220 mm Hg or diastolic blood pressure \\> 110 mm Hg);\n5. Baseline blood glucose \\\u003C50 mg\u002Fdl (2.8 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL);\n6. Baseline platelet count \\\u003C100 x10\\^9\u002FL;\n7. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with international normalized ratio \\> 1.7;\n8. Severe renal insufficiency, defined as serum creatinine \\> 3.0 mg\u002Fdl (or 265.2 μmol\u002Fl) or glomerular filtration rate \\[GFR\\] \\\u003C 30 ml\u002Fmin, or patients requiring hemodialysis or peritoneal dialysis;\n9. Patients that cannot complete 90-day follow-up (such as no fixed residence, overseas patients, etc.);\n10. Suspected vasculitis or septic embolism;\n11. Neurological diseases or mental disorders before onset that affect the assessment of the condition;\n12. Females who are pregnant or in lactation;\n13. Participating in other clinical trials that could confound the evaluation of the study;\n14. Subjects who, in the opinion of the investigator, have a life expectancy \\\u003C3 months due to conditions not related to current LHI or are unlikely to comply with follow-up requirements. Other conditions that the investigators believe are not suitable for participation or may pose a significant risk to the patient.\n\nNeuroimaging Exclusion Criteria\n\n1. Evidence of other brain diseases such as cerebral trauma, intracranial tumor (except small meningioma), cerebral aneurysm, etc.\n2. Evidence of acute ischemic infarction in bilateral anterior circulation territory or involvement of posterior circulation territories (other than in patients with a fetal or near-fetal PCA configuration);\n3. Vascular perforation during thrombectomy;\n4. The pre-randomization CT findings exhibits evidence of parenchymal hemorrhage 2 intracranial hemorrhage, diffuse severe subarachnoid hemorrhage, or intraventricular hemorrhage. Patients with localized mild subarachnoid hemorrhage, hemorrhagic infarction type1 or 2, and small parenchymal hematoma type 1 without midline shift may be included;","75 Years",{"count":75,"type":20},380,[23],"Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard first-line treatment for LVO, outcomes remain poor in patients with large ischemic cores (ASPECTS ≤5). Despite high recanalization rates (\\>90%), only 14-30% achieve functional independence (mRS 0-2) at 90 days, with 33-50% dead or severely disabled (mRS 5-6). Outcomes worsen dramatically with larger core volumes (e.g., only 4.4% functional independence with cores ≥150mL in SELECT2).A critical complication is Malignant Cerebral Edema (MCE), affecting \\~50% of large-core patients post-EVT. MCE triggers a vicious cycle of rising intracranial pressure, reduced perfusion, and brain herniation. It drastically worsens prognosis: functional independence rates plummet (13.3% vs 51.2% without MCE), mortality significantly increases (OR=7.96, p=0.001), and functional outcomes deteriorate (OR=7.83, p=0.008). Strong predictors include low ASPECTS (\\\u003C7) and large infarct volume.Decompressive Hemicraniectomy (DHC) is a life-saving intervention for MCE. Landmark trials (DESTINY, DECIMAL, HAMLET) and their meta-analysis show DHC within 24 hours in patients aged 18-60 significantly increases 12-month survival (78% vs 29%, ARR 50%) and rates of ambulatory independence (mRS ≤3: 43% vs 21%, ARR 23%). DESTINY II confirmed benefit in patients \\>60, improving functional outcomes (mRS 0-4: 38% vs 16%). Guidelines endorse DHC for large infarcts with deterioration.However, significant challenges persist:\n\nDHC is Underutilized: Despite evidence, clinical adoption remains low.Rescue DHC Fails to Improve Outcomes in Post-EVT MCE: Studies report poor functional outcomes (only 20% mRS 0-2) and high mortality (48.6%) with standard medical therapy (SMT) plus rescue DHC after MCE develops. Retrospective data confirms worse outcomes in these patients (mRS 0-2: 16.4% vs 50%; mortality: 46.5% vs 20%) compared to those without MCE. Crucially, rescue DHC itself fails to improve prognosis once MCE is established (mRS 5-6: 64% vs 57.7%; mortality: 48% vs 46.2%).High-Risk Identification: Patients defined as high-risk for MCE (ASPECTS 3-5 + NIHSS≥30 or ASPECTS≤2) have significantly worse 90-day outcomes (mRS 0-2: 23.2% vs 44.6%; mortality: 44% vs 22.7%).Timing is Critical: Rescue DHC is often performed too late, after irreversible neurological damage occurs. Early\u002FProphylactic DHC, performed before significant edema and herniation develop, offers a potential pathophysiological advantage. It may:Improve cerebral perfusion pressure earlier. Reduce mass effect and edema progression. Mitigate secondary injury (e.g., reduce oxygen-free radicals, excitatory amino acids).Potentially break the ischemic-edema-herniation cycle sooner.Rationale for the Study: While DHC is effective for established MCE in non-EVT contexts and rescue DHC post-EVT is ineffective, high-quality evidence for early prophylactic DHC in high-risk large-core patients after successful EVT is lacking. Current guidelines do not address this specific, high-risk population where MCE incidence is \\~50% and outcomes are dismal despite recanalization.\n\nStudy Aim: This trial will evaluate the efficacy and safety of early prophylactic decompressive hemicraniectomy compared to standard medical treatment (which includes rescue DHC if MCE develops) in AIS-LVO patients at high risk of MCE (defined by ASPECTS and NIHSS criteria) following successful EVT. The goal is to determine if proactive intervention can improve functional outcomes and reduce mortality in this critically ill population where current strategies fail.",[79,27],"Stroke, Ischemic",[81,82,27,83],"Acute Ischemic Stroke","Endovascular Thrombectomy","Hemicraniectomy","RECRUITING","2026-01-22",{"date":87,"type":33},"2026-01-26",{"date":89,"type":33},"2025-07-19",{"date":91,"type":20},"2029-06-19",{"name":93,"class":40},"Xuanwu Hospital, Beijing",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":41},"100555673","high-volume-versus-standard-volume-plasma-exchange-in-patients-with-acute-liver-failure-with-cerebral-edema-100555673","NCT06515145","High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema","To Evaluate the Safety and Efficacy of High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema -A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\nPatients with acute liver failure defined as patients with jaundice which is complicated by encephalopathy and coagulopathy within 4 weeks of the onset of jaundice and without underlying chronic liver disease.\n\nCerebral edema documented on CT-scan and arterial ammonia \\>150 ug\u002FdL\n\nExclusion Criteria:\n\n1. Age \\\u003C18 or \\> 70 years\n2. HCC\n3. Active untreated Sepsis\u002FDIC\n4. Hemodynamic instability non-responsive to initial fluid resuscitation with norepinephrine \\>0.1 ug\u002Fkg\u002Fmin\n5. Post-resection and malignancy related liver failure\n6. Coma of non-hepatic origin\n7. Patients with uncontrolled infection\n8. Patients with pulmonary involvement with Pa02\u002FFio2 ratio below 200.\n9. Patients with post renal obstructive AKI, AKI suspected due to glomerulonephritis, interstitial nephritis or vasculitis based on clinical history and urine analysis\n10. Extremely moribund patients with an expected life expectancy of less than 24 hours\n11. Pregnancy related liver failure\n12. Comorbidities associated with poor outcome (Extrahepatic neoplasia, severe cardiopulmonary disease defined by a New York Heart Association score \\>3, or oxygen\u002Fsteroid-dependent chronic obstructive pulmonary disease)\n13. Refusal to participate in the study\n14. Drug-induced ALF","70 Years",{"count":104,"type":20},60,[23],"In this prospective randomized controlled trial Investigator aim to evaluate the impact of high versus standard volume plasma-exchange in patients with acute liver failure with cerebral edema and clinical outcomes. ALF who meet the inclusion and exclusion criteria within the first 12 hours will be randomized into two groups\n\nInterventional - High-volume plasma exchange Active Comparator - Standard volume plasma exchange\n\nExpected outcome of the project-.\n\n1. Primary end points: Time to improvement in cerebral edema\n2. Secondary end points:\n\nTo study the adverse events of therapy (volume overload, pulmonary complications, allergic reactions) etc.\n\nTransplant-free survival at day 21",[108,27],"Acute Liver Failure",[110,111,112,113,114],"Plasma-exchange","systemic inflammatory response syndrome","lactate","CRRT","sepsis","2025-09-18",{"date":117,"type":33},"2025-09-19",{"date":119,"type":20},"2025-12-01",{"date":121,"type":20},"2026-03-01",{"name":123,"class":40},"Institute of Liver and Biliary Sciences, India"]